Delivering therapeutic peptides through the nose bypasses the blood-brain barrier and could enable a new class of non-invasive Alzheimer's treatments — though clinical validation is still needed.
~60% of dementiaAlzheimer's disease accounts for approximately 60% of all dementia cases, yet current treatments only manage symptoms — creating an urgent need for drug delivery innovations
What the researchers found
Intranasal delivery of therapeutic peptides can bypass the blood-brain barrier through nose-to-brain pathways, offering a non-invasive route to deliver Alzheimer's disease treatments directly to the brain. The review identifies key advantages: enhanced stability, rapid absorption, non-invasiveness, and improved patient compliance compared to injection-based delivery. Nanoparticle formulations can further improve the efficacy of intranasally delivered peptides by protecting them from degradation and enhancing their transport through nasal pathways.
Therapeutic peptides targeting critical AD pathological processes — including amyloid aggregation, tau phosphorylation, and neuroinflammation — are promising candidates for this delivery route. However, advancing from encouraging preclinical results to clinical applications remains the central challenge.
Why it matters
Alzheimer's disease accounts for nearly 60% of all dementia cases, yet current treatments only manage symptoms. Many promising peptide drugs fail because they can't cross the blood-brain barrier — the brain's protective wall that blocks most drugs. Nasal delivery offers a shortcut that bypasses this barrier entirely, potentially enabling a new generation of peptide-based Alzheimer's treatments that are both effective and easy to administer.
The numbers in context
AD = ~60% of dementia cases · nose-to-brain pathway bypasses BBB · non-invasive delivery · nanoparticle enhancement
How the study worked
Review covering Alzheimer's disease mechanisms, existing therapies, brain targeting challenges, nose-to-brain delivery pathways, and recent advances in intranasal peptide delivery technologies including nanoparticle-based formulations.
Who was studied
Alzheimer's disease patients — review focused on future therapeutic delivery strategies
What this study cannot tell us
Most evidence for intranasal peptide delivery in AD comes from preclinical animal studies. Translation to humans is complicated by anatomical differences in nasal passages, the challenge of consistent dosing, and the lack of long-term safety data for chronic nasal peptide administration. The blood-brain barrier bypass through nasal delivery is well-established in animals but less proven in human clinical settings for peptide-sized molecules.
How to read the evidence
This is a comprehensive review published in Biomaterials Advances that covers the theoretical basis and preclinical evidence for intranasal peptide delivery in AD. While the approach is scientifically sound, clinical validation in human Alzheimer's patients is still lacking.
When this study was published
Published in 2026 in Biomaterials Advances. Extremely current, representing the latest thinking on intranasal peptide delivery for neurodegenerative disease.
The bigger picture
The nose-to-brain delivery route is gaining traction across neurodegenerative diseases, not just Alzheimer's. If intranasal peptide delivery proves clinically effective, it could open the door to treating Parkinson's, ALS, and other brain diseases with peptide drugs that currently can't reach their target. The combination of therapeutic peptides with nanoparticle delivery through nasal pathways represents a convergence of three active research fields — peptide therapeutics, nanotechnology, and alternative drug delivery routes.
Questions still open
- Which specific therapeutic peptides for Alzheimer's are closest to intranasal clinical trials in humans?
- How does chronic daily nasal peptide administration affect nasal mucosa integrity over months and years?
- Can intranasal peptide delivery achieve therapeutic concentrations in deeper brain regions affected by Alzheimer's, not just superficial areas?
Common questions
How can a nasal spray deliver drugs to the brain?
Why use peptides for Alzheimer's instead of regular drugs?
Read the original research
Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.
Biomaterials advances, 178, 214474
Citation
Majie, Ankit; Karmakar, Varnita; Ghosh, Arya; Chakraborty, Snigdha; Apurva; Layek, Buddhadev; Gorain, Bapi. (2026). Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.. Biomaterials advances, 178, 214474. https://doi.org/10.1016/j.bioadv.2025.214474